# Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

> **NCT00045201** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Adult Solid Neoplasm

## Interventions

- **DRUG:** Erlotinib Hydrochloride
- **DRUG:** Irinotecan Hydrochloride

## Key facts

- **NCT ID:** NCT00045201
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2002-06-13
- **Primary completion:** 2013-09-13
- **Final completion:** 2026-08-22
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045201, "Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00045201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*